everolimus

P2, N=50, Not yet recruiting, Jonsson Comprehensive Cancer Center

P2/3, N=60, Not yet recruiting, Boston Children's Hospital | Trial completion date: Apr 2030 --> Sep 2030 | Initiation date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2030 --> Sep 2030

Methods We derived a novel PDX from a patient with hormone receptor negative, HER2-positive IBC refractory to neoadjuvant chemotherapy with Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP)...We performed short-tandem repeat (STR) profiling, plotted tumor growth curves for mice treated with alpelisib/everolimus vs. untreated, and immunohistochemistry (IHC), and performed clinical genomic assays...Conclusion We established a PDX of a HER2-positive IBC tumor with a PIK3CA hotspot mutation (H1047R) refractory to TCHP. Targeting the PI3K/mTOR pathway may be useful to overcome resistance in HER2-positive IBC with a H1047R mutation in PIK3CA.

P2, N=94, Not yet recruiting, Yonsei University

Collectively, our analysis describes the driver genes and mutation characteristics in SCC. The multi-cohort and network-based framework employed in this study identifies candidate hub genes that warrant further clinical investigation in cervical cancer.

P1/2, N=12, Not yet recruiting, Centre Hospitalier De Versailles

In cisplatin-ineligible MIBC, the KEYNOTE-905/EV-303 trial demonstrated significant survival benefit with perioperative enfortumab vedotin plus pembrolizumab. In advanced RCC, KEYMAKER-U03 demonstrated improved progression-free survival with HIF-2α-based triplet therapy, the LenCabo study supported lenvatinib plus everolimus in later lines and the CALYPSO trial highlighted limited benefit of empiric combinations without biomarker selection. Emerging approaches including transcriptomic stratification (OPTIC RCC) and circulating biomarkers (KIM-1, ctDNA) support a shift toward biologically guided treatment selection.

P=N/A, N=50, Active, not recruiting, King Chulalongkorn Memorial Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Dec 2027

Positron emission tomography/computed tomography in January 2023 raised concern for recurrence, and exploratory laparoscopy in March 2023 documented peritoneal metastatic disease, followed by four cycles of cisplatin given within the then-prevailing carcinoma-based diagnostic framework...After external review, everolimus plus anastrozole was started in May 2025...At the most recent available follow-up in April 2026, the patient had no documented death and remained under postoperative surveillance. Discussion and This case illustrates the diagnostic importance of repeated tissue reassessment and the practical value of minimally invasive surgery as a relatively low-burden means of resection, restaging, and tissue acquisition in a rare molecularly reclassified adnexal tumor.

Mice were randomized into vehicle control or four sequential treatment groups (Everolimus→Sunitinib [E→S], Sunitinib→Everolimus [S→E], Pazopanib→Sunitinib [P→S], Pazopanib→Everolimus [P→E]). This RCC PDOX platform faithfully preserves patient-specific biology-including metastatic propensity, engraftment efficiency, growth kinetics, and stromal dependency-while enabling real-time evaluation of sequential targeted therapies. Given the limited number of models tested, these findings provide proof-of-concept for individualized treatment exploration in advanced RCC and support future investigation of rational combinations with immune checkpoint blockade in humanized or immunocompetent systems.

Screening for drugs also revealed AKT1, TP53, and PIK3R4 as druggable hubs, and many drugs (e.g., Everolimus, Dabrafenib, Trabectedin) showing high-affinity interactions. The study discovers new prognostic markers (ATG4A, GABARAPL2, GAPDH) and druggable targets, which could lead to better risk stratification and smarter drug repurposing. While restricted to in silico analyses, the integrative approach provides a basis for subsequent laboratory confirmation and translational development.

Telotristat ethyl exhibits antitumoral activity in neuroendocrine tumor models in vivo. Moreover, the combination of telotristat ethyl and everolimus, two therapies already used in clinical practice, may represent a safe and effective therapeutic strategy for neuroendocrine tumors.